Table 2.
Potential TAAs identified in lung cancer.
| TAAs | Gene Function | Histology | Identified Year | References |
|---|---|---|---|---|
| OLFM1 | Suppress cell growth and metastasis | LC | 2015 | [49] |
| SQLE | Cell proliferation and metastasis | LC | 2015 | [49] |
| c-Myc | Cell growth and metabolism | LC | 2016 | [50] |
| HNRNPA2B1 | mRNA metabolism and transport | LC | 2017 | [51] |
| ENO1 | Regulate cell proliferation and metastasis | NSCLC | 2017 | [52] |
| P53 | Inducing cell cycle arrest, and DNA repair | LC | 2017 | [53] |
| GBU4-5 | Cell growth and division | SCLC | 2018 | [54] |
| IGFBP-1 | Cell migration | LC | 2019 | [38] |
| FGFR1 | stem cell leukemia/lymphoma syndrome | LC | 2019 | [55] |
| CA125 | Cell adhesion, migration, and invasion | NSCLC | 2019 | [56] |
| GAGE7 | Influence cancer progression | NSCLC | 2019 | [57] |
| TOP2A | Metabolism for proteins and DNA damage | LC | 2020 | [58] |
| SOX2 | Cell proliferation, metastasis, and drug resistance | LC | 2020 | [59] |
| CAGE | Cell cycle, growth, and proliferation | NSCLC | 2021 | [60] |
Abbreviations: TAAs, tumor-associated antigens; LC, lung cancer; NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer.